|
**Overview**: GM1 Gangliosidosis Panel**Introduction**: The GM1 Gangliosidosis Panel is a diagnostic tool designed to screen for GM1 gangliosidosis using whole blood samples. In India, GM1 gangliosidosis (GLB1 deficiency) is a rare lysosomal storage disorder (~1 in 100,000â€"200,000 births), presenting in infantile form with developmental regression, hepatosplenomegaly, cherry-red spot, coarse facies, and neurodegeneration, or later-onset forms with ataxia/dystonia. High morbidity from underdiagnosis in rural/low-SES children with unexplained regression or seizures, limited genetic/enzyme labs, delayed supportive care leading to rapid deterioration or death by early childhood in severe cases. Per molecular pathology practices aligned with ICMR and Indian Society of Human Genetics guidelines, the test employs PCR for GLB1 gene mutations and beta-galactosidase activity over 1-2 days with high accuracy, valuable for confirming diagnosis in suspected lysosomal storage disorders. This diagnostic falls under genetic disorder screening and targets infants/children with neuroregression, organomegaly, or family history, addressing accurate detection to guide palliative care, genetic counseling, and potential enzyme replacement trials. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing lysosomal storage disorder burden. Its whole blood-based approach ensures reliable enzyme/mutation analysis.**Other Names**: GM1 Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/cytogenetics, compliant with 2025 standards.**Historical Milestone**: GLB1 testing standard; in India, used in rare disease clinics.**Purpose**: The test assesses 2 parameters including GLB1 gene mutation to guide GM1 gangliosidosis screening, confirm deficiency, inform counseling.**Test Parameters**: 1. GLB1 Gene Mutation, 2. Beta-Galactosidase Activity.**Pretest Condition**: No fasting required; patients should report developmental regression or organomegaly.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for analysis).**Medical History**: Patients should provide details on regression onset, seizures, family history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed GM1 including neurodegeneration, benefits of confirmation, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR and enzyme assay by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low enzyme activity can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Mutation/low activity confirms GM1 gangliosidosis, necessitating specialist input. Normal may require follow-up.**Specialist Consultation**: Pediatric neurologists or geneticists should be consulted for management.**Additional Supporting Tests**: Urine oligosaccharides, MRI brain for confirmation.**Test Limitations**: May miss rare variants; comprehensive approach required.**References**: Indian Journal of Pediatrics 2024, Metabolic Studies India 2023. |
